ReviewThe American journal of the medical sciences2002
Therapeutic applications of monoclonal antibodies.
Review in The American journal of the medical sciences, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 164 citations in OpenAlex.
- Targeting Undruggable Proteins: The siRNA Revolution Beyond Small Molecules - Advances, Challenges, and Future Prospects in Therapeutic Innovation.Current gene therapy · 2026Review
- Developing Biosimilars: Challenges and Opportunities.Pharmaceutical medicine · 2025Review
- Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine.International journal of molecular sciences · 2025Review
- Safety and tolerability of a novel monoclonal antibody cocktail for rabies post-exposure prophylaxis.NPJ vaccines · 2025Article
- Comparative Forced Degradation Study of Anticomplement C5 Biosimilar and Originator Monoclonal Antibodies.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Comprehensive bioinformatics and immunohistochemical analyses identify phosphoinositide metabolism and PNPLA7 as potential biomarkers in urological cancers.Scientific reports · 2025Article
- Multi-scale design and optimization of antibody production via flexible nets.Computational and structural biotechnology journal · 2025Article
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Therapeutic antibodies in oncology: an immunopharmacological overview.Cancer immunology, immunotherapy : CII · 2024Review
- Adsorption of monoclonal antibody fragments at the water-oil interface: A coarse-grained molecular dynamics study.APL bioengineering · 2024Article
- Article
- Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation.Journal of biological engineering · 2024Article
- Development of Analytical Method for the Quantitation of Monoclonal Antibodies Solutions via Raman Spectroscopy: The Case of Bevacizumab.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Unraveling the Microscopic Mechanism of Molecular Ion Interaction with Monoclonal Antibodies: Impact on Protein Aggregation.Molecular pharmaceutics · 2024Article
- Mechanistic Insights into the Adsorption of Monoclonal Antibodies at the Water/Vapor Interface.Molecular pharmaceutics · 2024Article
- Production and Purification of Antibodies in Chinese Hamster Ovary Cells.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Article
- Evaluation of the Potential Impact of In Silico Humanization on VInternational journal of molecular sciences · 2023Article
- Contemporary Monoclonal Antibody Utilization in Glomerular Diseases.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023Review
- Physiologic Changes During Pregnancy and Impact on Small-Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response.Journal of clinical pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Researchers have sought therapeutic applications for monoclonal antibodies since their development in 1975. However, murine-derived monoclonal antibodies may cause an immunogenic response in human patients, reducing their therapeutic efficacy. Chimeric and humanized antibodies have been developed that are less likely to provoke an immune reaction in human patients than are murine-derived antibodies. Antibody fragments, bispecific antibodies, and antibodies produced through the use of phage display systems and genetically modified plants and animals may aid researchers in developing new uses for monoclonal antibodies in the treatment of disease. Monoclonal antibodies may have a number of promising potential therapeutic applications in the treatment of asthma, autoimmune diseases, cancer, poisoning, septicemia, substance abuse, viral infections, and other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.